Notably, the use of PAH-specific medications such phosphodiesterase type 5 (PDE5) inhibitors, endothelin receptor antagonists (ETRA), guanylate cyclase (GC) stimulators or prostacyclin analogs did not significantly impact on the frequency of anemia or ID in our patient cohort. Here, GC is linked to pulmonary arterial hypertension.